B-Type Natriuretic Peptide Predicts Sudden Death in Patients With Chronic Heart Failure

Background—Given the high incidence of sudden death in patients with chronic heart failure (CHF) and the efficacy of implantable cardioverter-defibrillators, an appropriate tool for the prediction of sudden death is desirable. B-type natriuretic peptide (BNP) has prognostic significance in CHF, and the stimuli for its production cause electrophysiological abnormalities. This study tests BNP levels as a predictor of sudden death. Methods and Results—BNP levels, in addition to other neurohormonal, clinical, and hemodynamic variables, were obtained from 452 patients with a left ventricular ejection fraction (LVEF) ≤35%. For prediction of sudden death, only survivors without heart transplantation (HTx) or a mechanical assist device and patients who died suddenly were analyzed. Up to 3 years, 293 patients survived without HTx or a mechanical assist device, 89 patients died, and 65 patients underwent HTx. Mode of death was sudden in 44 patients (49%), whereas 31 patients (35%) had pump failure and 14 patients (16%) died from other causes. Univariate risk factors of sudden death were log BNP (P =0.0006), log N-terminal atrial natriuretic peptide (P =0.003), LVEF (P =0.005), log N-terminal BNP (P =0.006), systolic blood pressure (P =0.01), big endothelin (P =0.03), and NYHA class (P =0.04). In the multivariate model, log BNP level was the only independent predictor of sudden death (P =0.0006). Using a cutoff point of log BNP <2.11 (130 pg/mL), Kaplan-Meier sudden death–free survival rates were significantly higher in patients below (99%) compared with patients above (81%) this cutoff point (P =0.0001). Conclusion—BNP levels are a strong, independent predictor of sudden death in patients with CHF.

[1]  Timothy R Church,et al.  B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. , 2003, Circulation.

[2]  I. R. Manousos,et al.  Clinical trials update: The Heart Protection Study, IONA, CARISA, ENRICHD, ACUTE, ALIVE, MADIT II and REMATCH , 2002, European journal of heart failure.

[3]  G. Laufer,et al.  Survival Benefit of the Implantable Cardioverter-Defibrillator in Patients on the Waiting List for Cardiac Transplantation , 2001, Circulation.

[4]  E. Hartter,et al.  Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. , 2001, Journal of the American College of Cardiology.

[5]  L. Lenert,et al.  A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. , 2001, Journal of the American College of Cardiology.

[6]  W. Stevenson,et al.  Prevention of Sudden Death in Heart Failure , 2001, Journal of cardiovascular electrophysiology.

[7]  H. Isobe,et al.  Activated Protein C Prevents Endotoxin-Induced Hypotension in Rats by Inhibiting Excessive Production of Nitric Oxide , 2001, Circulation.

[8]  S. Connolly,et al.  Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study. , 2000, European heart journal.

[9]  M. Gold,et al.  Primary Prevention of Sudden Cardiac Death with Implantable Cardioverter Defibrillators: Lessons Learned From MADIT and MUSTT , 2000, Pacing and clinical electrophysiology : PACE.

[10]  D. Rosenbaum,et al.  Can Sudden Cardiac Death Be Predicted from the T Wave of the ECG? A Critical Examination of T Wave Alternans and QT Interval Dispersion , 2000, Pacing and clinical electrophysiology : PACE.

[11]  P. Krishnaswamy,et al.  A rapid bedside test for B‐type natriuretic peptide predicts treatment outcomes in patients admitted with decompensated heart failure , 2000 .

[12]  P. Binkley,et al.  The Problem of Ventricular Dysrhythmias and Sudden Death Mortality in Heart Failure: The Impact of Current Therapy , 2000, Cardiology.

[13]  J. Burnett,et al.  Natriuretic peptides in the pathophysiology of congestive heart failure , 2000, Current cardiology reports.

[14]  C. Frampton,et al.  Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations , 2000, The Lancet.

[15]  B. Massie,et al.  Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. PROMISE (Prospective Randomized Milrinone Survival Evaluation) Investigators. , 2000, Circulation.

[16]  S. Connolly.  Evidence-based analysis of amiodarone efficacy and safety. , 1999, Circulation.

[17]  Horng H. Chen,et al.  The natriuretic peptides in heart failure: diagnostic and therapeutic potentials. , 1999, Proceedings of the Association of American Physicians.

[18]  R. Doughty,et al.  Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. , 1999, Circulation.

[19]  C. Frampton,et al.  Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. , 1998, Circulation.

[20]  H. Tunstall-Pedoe,et al.  Biochemical detection of left-ventricular systolic dysfunction , 1998, The Lancet.

[21]  J. Mason,et al.  Predictors of arrhythmic death and cardiac arrest in the ESVEM trial. Electrophysiologic Study Versus Electromagnetic Monitoring. , 1997, Circulation.

[22]  D. Fukai,et al.  Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. , 1997, Circulation.

[23]  D. Packer,et al.  Impact of volume loading and load reduction on ventricular refractoriness and conduction properties in canine congestive heart failure. , 1997, Journal of the American College of Cardiology.

[24]  S. Dubner,et al.  Nonsustained ventricular tachycardia in severe heart failure. Independent marker of increased mortality due to sudden death. GESICA-GEMA Investigators. , 1996, Circulation.

[25]  M J Reiter,et al.  Effects of mechano-electrical feedback: potential arrhythmogenic influence in patients with congestive heart failure. , 1996, Cardiovascular research.

[26]  M. Schoenfeld,et al.  Exploration of the precision of classifying sudden cardiac death. Implications for the interpretation of clinical trials. , 1996, Circulation.

[27]  D. Kass,et al.  Sudden cardiac death in heart failure. The role of abnormal repolarization. , 1994, Circulation.

[28]  Z Wang,et al.  Initiation of ventricular extrasystoles by myocardial stretch in chronically dilated and failing canine left ventricle. , 1994, Circulation.

[29]  H. Crijns,et al.  Value of ambulatory electrocardiographic monitoring to identify increased risk of sudden death in patients with left ventricular dysfunction and heart failure. , 1994, European heart journal.

[30]  W. Stevenson,et al.  Sudden Death Prevention in Patients With Advanced Ventricular Dysfunction , 1993, Circulation.

[31]  S. Connolly,et al.  Standardized Reporting of ICD Patient Outcome: The Report of a North American Society of Pacing and Electrophysiology Policy Conference, February 9–10, 1993 , 1993, Pacing and clinical electrophysiology : PACE.

[32]  J. Cohn,et al.  Mechanism of Death in Heart Failure The Vasodilator‐Heart Failure Trials , 1993, Circulation.

[33]  M R Franz,et al.  Electrophysiological Effects of Myocardial Stretch and Mechanical Determinants of Stretch‐Activated Arrhythmias , 1992, Circulation.

[34]  W G Stevenson,et al.  Prognostic Significance of Atrial Fibrillation in Advanced Heart Failure: A Study of 390 Patients , 1991, Circulation.

[35]  L. Hondeghem,et al.  Stretch-induced arrhythmias in the isolated canine ventricle. Evidence for the importance of mechanoelectrical feedback. , 1990, Circulation.

[36]  J. Rouleau,et al.  Long-term predictors of sudden and low output death in chronic congestive heart failure secondary to coronary artery disease. , 1989, The American journal of cardiology.

[37]  B. Pitt,et al.  Predictors of total mortality and sudden death in mild to moderate heart failure. Captopril-Digoxin Study Group. , 1989, Journal of the American College of Cardiology.

[38]  E. Keeler,et al.  Primer on certain elements of medical decision making. , 1975, The New England journal of medicine.